How Can CDMOs Provide Flexibility In Upstream Production That Will Improve Their Customers' Speed To Market?

By Adrian Mazzone and Lee Stevens, Thermo Fisher Scientific

For CDMOs, it is not economical ― or even possible ― to change your facility setup each time you begin production for a new or existing client. However, every day that passes is a day there are patients waiting for their therapeutic, as well competitors racing to get their product on the market first. In this environment, the time it takes to get a drug manufactured and into clinical trials is critical to the success of not only your clients but also of your own company. Therefore, in order to provide the best service, your facility should be equipped with flexible manufacturing platforms that can be adjusted for multiple customers while also mitigating risk.